A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

A Phase 1, Open-label Study to Evaluate PF-08046044/SGN-35C in Adults With Advanced Malignancies.

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).

This clinical trial uses a drug called PF-08046044/SGN-35C . The study drug is in testing and has not been approved for sale. This is the first time SGN -35C will be used in people.

This study will test the safety of SGN-35C in participants with lymphoma. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.

This study will have three parts. Parts A and B of the study will find out the best dose and dosing schedule for SGN-35C. Part C will use the dose found in parts A and B to find out how safe SGN-35C is and if it works to treat select lymphomas.

Study Overview

• Status: Terminated
• Conditions: Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Lymphoma, Large-Cell, Anaplastic
• Intervention / Treatment: Drug: PF-08046044/SGN-35C

• Study Type: Interventional
• Enrollment (Actual): 58
• Phase: Phase 1

Contacts and Locations

Study Locations

• Denmark
  • Copenhagen Ø, Denmark, DK 2100
    • Rigshospitalet University Hospital of Copenhagen
• France
  • Villejuif, France, 94805
    • Institut Gustave Roussy
• Italy
  • Verona, Italy, 37134
    • Centro Ricerche Cliniche di Verona S.r.l.
• Spain
  • Barcelona, Spain, 08035
    • Hospital Universitari Vall d'Hebron
• United Kingdom
  • Manchester, United Kingdom, M20 4BX
    • The Christie NHS Foundation Trust
  • Surrey
    • Sutton, Surrey, United Kingdom, SM2 5PT
      • The Royal Marsden NHS Foundation Trust (RM)
• United States
  • California
    • Duarte, California, United States, 91010
      • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
    • Duarte, California, United States, 91010
      • IP Address: City of Hope Investigational Drug Services(IDS)
    • San Francisco, California, United States, 94143
      • University of California, San Francisco Medical Center
  • Florida
    • Coral Gables, Florida, United States, 33146
      • Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center
    • Deerfield Beach, Florida, United States, 33442
      • University of Miami Hospital and Clinics - Deerfield Beach
    • Hollywood, Florida, United States, 33021
      • Sylvester Comprehensive Cancer Center - Hollywood
    • Miami, Florida, United States, 33136
      • University Of Miami Hospital and Clinics/Sylvester Comprehensive Cancer Center
    • Miami, Florida, United States, 33136
      • University Of Miami Hospitals And Clinics
    • Miami, Florida, United States, 33176
      • Sylvester Comprehensive Cancer Center - Kendall
  • Kansas
    • Fairway, Kansas, United States, 66205
      • University of Kansas Clinical Research Center
    • Fairway, Kansas, United States, 66205
      • The University of Kansas Cancer Center, Investigational Drug Services
    • Kansas City, Kansas, United States, 66160
      • The University of Kansas Hospital
    • Kansas City, Kansas, United States, 66160
      • The University of Kansas Medical Center Medical Office Building
    • Kansas City, Kansas, United States, 66160
      • The University of Kansas Hospital Cambridge North Tower A
    • Overland Park, Kansas, United States, 66210
      • The University of Kansas Cancer Center - Overland Park
    • Overland Park, Kansas, United States, 66211
      • The University of Kansas Cancer Center - Indian Creek Campus
    • Westwood, Kansas, United States, 66205
      • University of Kansas Cancer Center
  • Missouri
    • Lee's Summit, Missouri, United States, 64064
      • The University of Kansas Cancer Center - Lee's Summit
  • Nebraska
    • Bellevue, Nebraska, United States, 68123
      • Nebraska Medicine - Bellevue Medical Center
    • Omaha, Nebraska, United States, 68198
      • University of Nebraska Medical Center
    • Omaha, Nebraska, United States, 68118
      • Nebraska Medicine - Village Pointe
    • Omaha, Nebraska, United States, 68105
      • Nebraska Medical Center
  • New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Rutgers Cancer Institute of New Jersey
    • New Brunswick, New Jersey, United States, 08901
      • Robert Wood Johnson University Hospital
  • Washington
    • Seattle, Washington, United States, 98195
      • University of Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center | Seattle, WA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Tumor type

• For dose escalation and back fill and dose optimization (Parts A and B):

  • Participants with a histologically confirmed lymphoid neoplasm who in the judgement of the investigator have no appropriate standard therapy available at the time of enrollment and are a candidate for PF-08046044/SGN- 35C treatment. Eligible subtypes and treatment status are as follows:

    • Participants with relapsed/refractory (R/R) cHL: should have received at least 3 prior systemic therapies including autologous stem cell transplant [ASCT] (ASCT and the associated high-dose chemotherapy prior to ASCT are considered to be 1 prior line, along with post-transplant consolidation if progression has not occurred between transplant and start of consolidation) or an anti-PD-1 agent (or refused/were ineligible); or 2 prior systemic therapies if, according to the investigator, no other appropriate standard treatment is available.
    • Participants with R/R PTCL (excluding systematic anaplastic large cell lymphoma [sALCL]): should have received at least 2 prior systemic therapies, or 1 prior systemic therapy if, according to the investigator, no other appropriate standard treatment is available.
    • Participants with R/R sALCL: should have received at least 2 prior systemic therapies, including 1 brentuximab vedotin-containing regimen, or 1 prior line of systemic therapy including brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone.
    • Participants with R/R DLBCL: should have received at least 2 prior systemic therapies, including ASCT and chimeric antigen receptor (CAR) T-cell therapy, or were ineligible, or refused.
  • Participants with PTCL and DLBCL must have a detectable cluster of differentiation 30 (CD30) expression level (≥1%) in tumor tissue from the most recent biopsy obtained at or after relapse by local testing.

• For dose expansion (Part C):

  • Participants are eligible irrespective of CD30 expression on tumor tissue; however, participants must provide tumor tissue for evaluation of CD30 expression from the most recent biopsy obtained at or after relapse.
  • Participants with cHL, PTCL, sALCL, and DLBCL: Eligible subtypes are the same as defined in Parts A and B
  • If activated, the biology cohort may enroll the populations included in Parts A, B, and C.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1
• Fluorodeoxyglucose positron emission tomography (FDG-PET) avid and bidimensional measurable disease as documented by radiographic technique (spiral computed tomography [CT] preferred)

Exclusion Criteria:

• Previous exposure to any antibody-drug conjugates (ADCs) with camptothecin-based payload.
• History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death
• Active central nervous system (CNS) disease related to the underlying malignancy. Participants with a history of CNS disease related to the underlying malignancy are allowed if prior CNS disease has been treated and the participant is clinically stable (defined as not currently receiving steroid treatment for symptoms related to cerebral/meningeal disease and with no ongoing related AE).
• Received previous ASCT infusion <12 weeks prior to the first dose of SGN-35C.

• Previous allogeneic stem cell transplant (SCT) if they meet any of the following criteria:

  • <100 days from allogeneic SCT. Participants ≥100 days from allogeneic SCT who are stable without immunosuppressive therapy for at least 12 weeks are permitted.
  • Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD.
• History of clinically significant GI bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of trial treatment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PF-08046044/SGN-35C; PF-08046044/SGN-35C Monotherapy	Drug: PF-08046044/SGN-35C; Given into the vein (IV; intravenously)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with dose-limiting toxicities (DLTs)		Up to 21 days
Number of participants with adverse events (AEs)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention	Through 30-37 days after last study treatment, approximately 1 year
Number of participants with laboratory abnormalities		Through 30-37 days after last study treatment, approximately 1 year
Number of participants with dose modifications due to AEs		Up to approximately 1 year
Number of participants with DLTs by dose level		Up to 21 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with antidrug antibodies (ADA)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Area under the concentration time curve (AUC)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Maximum concentration (Cmax)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Time at which the maximum concentration occurs (Tmax)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Apparent terminal half-life (t1/2)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Trough concentration (Ctrough)	To be summarized using descriptive statistics	Through 30-37 days after last study treatment, approximately 1 year
Objective response rate (ORR) as assessed by the investigator	A participant is determined to have an objective response if, based on Lugano criteria (Cheson 2014), they achieve a complete response (CR) or partial response (PR) as assessed by the investigator. The ORR is defined as the percentage of participants with an objective response.	Up to approximately 1 year
CR rate as assessed by the investigator	CR rate is defined as the proportion of participants with CR.	Up to approximately 1 year
Duration of response (DOR)	DOR is defined as the time from the start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per Lugano criteria (Cheson 2014) as assessed by the investigator or to death due to any cause, whichever comes first.	Up to approximately 1 year

Collaborators and Investigators

• Sponsor: Seagen, a wholly owned subsidiary of Pfizer
• Investigators: Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): May 28, 2024
• Primary Completion (Actual): April 13, 2026
• Study Completion (Actual): April 13, 2026

Study Registration Dates

• First Submitted: February 2, 2024
• First Submitted That Met QC Criteria: February 2, 2024
• First Posted (Actual): February 12, 2024

Study Record Updates

• Last Update Posted (Actual): May 8, 2026
• Last Update Submitted That Met QC Criteria: May 4, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: DLBCL; PTCL; Seattle Genetics; ADC; sALCL; cHL; Anti Drug Conjugate
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma; Lymphoma, T-Cell; Hemic and Lymphatic Diseases; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, T-Cell, Peripheral; Lymphoma, Large-Cell, Anaplastic; Antineoplastic Agents, Immunological; Antineoplastic Agents; Immunologic Factors; Physiological Effects of Drugs; Immunoconjugates; Immunotoxins; Brentuximab Vedotin
• Other Study ID Numbers: SGN35C-001; C5801001 (Other Identifier: Alias Study Number); 2023-505813-26-00 (Registry Identifier: CTIS (EU))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No